NNE has delivered the conceptual and basic design for Novo Nordisk's Kalundborg manufacturing site expansion and can now start the construction.
Novo Nordisk announced plans to invest more than DKK 42bn ($6.2m) to expand existing manufacturing facilities in Kalundborg, Denmark, starting in 2023, and NNE has been assigned the engineering task as Novo Nordisk’s partner from design to construction.
We are designing a facility at the forefront of technology, making it future-proof in terms of pharmaceutical production and sustainability
This comes after Novo Nordisk previously announced plans to invest more than DKK 17bn ($2.5m) in the construction of three new manufacturing facilities as well as the expansion of one existing facility at the production site in Kalundborg.
This huge expansion signifies one of the largest projects in NNE history.
CEO of NNE, Jesper Kløve, said: “I want to thank Novo Nordisk for assigning NNE this major project. Being entrusted with something so important comes with responsibility, and we will do our utmost to deliver an excellent result using our capabilities and expertise within the pharma engineering field. Our dedicated team of professionals has already started the initial work to ensure the new facility will live up to the highest standards. We are designing a facility at the forefront of technology, making it future-proof in terms of pharmaceutical production and sustainability. NNE has a proven track record of completing complex engineering projects on time and within budget, and we are committed to maintaining this high standard on this new project. We are looking forward to collaborating with Novo Nordisk to bring their vision to life.”